228 related articles for article (PubMed ID: 23984925)
1. Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know.
Steiner S; Moertl D
Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):975-84. PubMed ID: 23984925
[TBL] [Abstract][Full Text] [Related]
2. New antiplatelet agents in the treatment of acute coronary syndromes.
Sabouret P; Taiel-Sartral M
Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
[TBL] [Abstract][Full Text] [Related]
3. Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
Med Lett Drugs Ther; 2011 Sep; 53(1372):69-70. PubMed ID: 21897348
[TBL] [Abstract][Full Text] [Related]
4. New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
Sinhal AR; Aylward PE
Clin Ther; 2013 Aug; 35(8):1064-8. PubMed ID: 23973039
[TBL] [Abstract][Full Text] [Related]
5. New anti-platelet agents: the end of resistance?
Kastrati A
Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Coleman CI; Limone BL
Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet options for secondary prevention in acute coronary syndromes.
Silvain J; Cayla G; O'Connor SA; Collet JP; Montalescot G
Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1403-15. PubMed ID: 22059790
[TBL] [Abstract][Full Text] [Related]
8. Prasugrel: a new antiplatelet drug for the prevention and treatment of cardiovascular disease.
Koo MH; Nawarskas JJ; Frishman WH
Cardiol Rev; 2008; 16(6):314-8. PubMed ID: 18923235
[TBL] [Abstract][Full Text] [Related]
9. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
Azmoon S; Angiolillo DJ
Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
[TBL] [Abstract][Full Text] [Related]
11. [Platelet function: new drugs, new assays : possible impacts on operative medicine?].
Mahla E; Höchtl T; Prüller F; Freynhofer MK; Huber K
Anaesthesist; 2012 Jun; 61(6):483-96. PubMed ID: 22695779
[TBL] [Abstract][Full Text] [Related]
12. Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
Orban M; Riegger J; Joner M; Tada T; Okrojek R; Hausleiter J; Kastrati A; Massberg S; Sibbing D
Platelets; 2012; 23(5):395-8. PubMed ID: 22671583
[TBL] [Abstract][Full Text] [Related]
13. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
[TBL] [Abstract][Full Text] [Related]
14. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
[TBL] [Abstract][Full Text] [Related]
15. Prasugrel: Clinical development and therapeutic application.
Guerra DR; Tcheng JE
Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231
[TBL] [Abstract][Full Text] [Related]
16. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
Tcheng JE; Mackay SM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):83-91. PubMed ID: 22316323
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
Norgard NB; Dinicolantonio JJ
Postgrad Med; 2013 Jul; 125(4):91-102. PubMed ID: 23933898
[TBL] [Abstract][Full Text] [Related]
18. Ticagrelor: a novel reversible oral antiplatelet agent.
Nawarskas JJ; Clark SM
Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
[TBL] [Abstract][Full Text] [Related]
19. Advances in the monitoring of anti-P2Y12 therapy.
Harrison P
Platelets; 2012; 23(7):510-25. PubMed ID: 22916724
[TBL] [Abstract][Full Text] [Related]
20. Update on oral antiplatelet therapy: principles, problems and promises.
Grove EL; Kristensen SD
Future Cardiol; 2009 May; 5(3):247-58. PubMed ID: 19450051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
